Mechanism of photodynamic occlusion using liposomal Zn(II)-phtalocyanine

Current Eye Research

Volumn 30, Issue 7, 2005, Pages 601-612

  Schmidt Erfurth, Ursula ^a,d   Michels, Stephan ^a   Indorf, Lars ^a   Eggers, Reinhard ^b   Birngruber, Reginald ^c  

^a Österreichische Akademie für Augenheilkunde und Optometrie   (Austria)

^b Institut fur Anatomie   (Germany)

^c Institut für Lasermedizin GmbH   (Germany)

^d NONE   (Austria)

Author keywords

Choroidal vasculature; Liposomes; Photodynarnic therapy; Zinc(II) phtalocyanine

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; LIPOSOME; PHTHALOCYANINE ZINC;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HISTOLOGY; NONHUMAN; OCCLUSION; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PIGMENT EPITHELIUM; PIGMENTATION; PRIORITY JOURNAL; RABBIT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD VESSELS; CAPILLARY PERMEABILITY; CHOROID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUORESCEIN ANGIOGRAPHY; INDOLES; LIPOSOMES; ORGANOMETALLIC COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTORECEPTORS, VERTEBRATE; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; RABBITS; RETINAL VESSELS;

EID: 23444442216     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680590968286     Document Type: Article

References (30)

1. The Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin. Arch Ophthalmol. 2001;198-207.
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult and no classic choroidal neovascularization. Am J Ophthalmol. 2001;131:541-60.
3. Thomas EL, Tressler CS, Murphy RP. Efficacy of SnET2 photodynamic therapy for choroidal neovascularization in age-related macular degeneration: phase III pivotal trial results (ARVO Abstract). Invest Ophthalmol Vis Sci. 2002;43:40. Abstract 983.
4. Blumenkranz MS, Woodburn KW, Quing F, et al. Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy. Am J Ophthalmol. 2000;129:353-362.
5. Schmidt-Erfurth U, Michels S et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841.
6. Isele U, van Hoogevest P, Hilfiker R, et al. Large scale production of liposomes containing monomeric zinc phthalocyanine by controlle dilution of organic solvents. J Pharm Sci. 1994;83:1608-1616.
7. Schieweck K, Ochsner M, Capraro HG, Isele U, et al. Investigator's brochure, CGP 55 847 Liposomal zinc (II)-phthalocyanine (Photosensitizer). Ciba-Geigy limited Pharma Division 1994:1-34.
8. Schmidt-Erfurth U, Hasan T, Gragoudas E, et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101:1953-1961.
9. Gomer CJ, Rucker N, Murphree AL. Differential cell photosensitivity following porphyrin photodynamic therapy. Cancer Res. 1988; 48:4539-4542.
10. Povlishock TJ, Rosenblum WI, Sholley MM, Wei EP. An ultrastructural analysis of endothelial change paralleling platelet aggregation in a light/dye model of microvascular insult. Am J Pathol. 1983;110:148-160.
11. Schmidt-Erfurth U, Hasan T, Schomacker K, et al. In-vivo uptake of liposomal benzporphyrin derivative and photothrombosis in experimental corneal neovascularization. Laser Surg Med. 1995;17:178-188.
12. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
13. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology. 1999;106:1915-1923.
14. Zacks DN, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci. 2002;43:2384-2391.
15. Peyman GA, Kazi AA, Unal M, et al. Problems with and pitfalls of photodynamic therapy. Ophthalmology. 2000;107:29-35.
16. Schmidt-Erfurth U, Michels S. Long-term changes in confocal indocyanine green angiography following photodynamic therapy. Ophthalmology. 2003;110:1306-1314.
17. Khoobehi B, Grinstead R, Passos E. Experimental photodynamic effects of hypocrellin A of the choriocapillaris. Ophthalmic Surg Lasers. 2002;33:207-213.
18. Zhou C, Milanesi C, Jori G. An ultrastructural comparative evaluation of tumours photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins. Photochem Photobiol. 1988;48:487-492.
19. Jori G, Reddi E. Strategies for tumor targeting by photodynamic sensitizers. In: Kessel D. Photodynamic Therapy of Neoplastic Disease. Boca Raton, FL: CRC press; 1990:117-130.
20. Gal D, McDonald PC, Porter JC, et al. Cholesterol metabolism in cancer cells in monolayer culture.II. Low density lipoprotein metabolism. Int J Cancer. 1981;28:315-319.
21. Fracasso PM, Rodriguez LC, Herzog TJ, et al. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer. 2003;98:610-617.
22. Schmidt-Erfurth U, Diddens H, Birngruber R, et al. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer. 1997;75:54-61.
23. Allison BA, Pritchard PH, Levy J. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer. 1994;69:833-839.
24. Gijsens A, Derycke A, Missiaen L, et al. Targeting of the photocytotoxic compound AIPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer. 2002;101:78-85.
25. Voyta JC, Via DP, Butterfield CE, et al. Identification and isolation of endothelial cells based on their increased uptake of acetylated low-density lipoprotein. J Cell Biol. 1984;99:2034-2040.
26. Vlodavsky I, Fielding PE, Fielding CJ et al. Role of contact inhibition in the regulation of receptor-mediated uptake of low density lipoprotein in cultured vascular endothelial cells. Proc Natl Acad Sci USA. 1978;75:356-360.
27. Takeuchi Y, Kurohane K, Ichikawa K, et al. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer. 2003;15:2027-2034.
28. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy of choroidal neovascularization due to age-related macular degeneration using verteporfin: Results of single treatments in a phase I an II study. Arch Ophthalmol. 199;117:1161-1177.
29. Michels S, Schmidt-Erfuerh U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44:2147-2154.
30. Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefe's Arch Clin Exp Ophthalmol. 2002;240:748-757.